The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.
Envision Pharma Group, a leading global technology-enabled scientific communications company, announced the acquisition of Two Labs, an industry-leading provider of integrated and customized commercial solutions to the pharmaceutical and biotechnology sector.
Huntsworth, an international healthcare and communications group, announced an agreement to acquire Nucleus Global, one of the world’s largest medical specialist communications groups.
The Healthcare Technology Report announced the Top 25 Women Leaders in Biotechnology of 2020.
Additional findings from Biogen’s Phase II LILAC study show the biotech company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus (SLE).
Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
RA Capital Management closed the venture capital firm’s second venture fund at $461 million, aimed at a continued investment strategy into privately held life sciences companies.
Will the solitary path the United States is on, insulate it from further Covid-19 pandemic-related damage? Christopher Snyder, a professor of economics at Dartmouth University, believes the answer depends largely on the eventual vaccine’s level of efficacy.
Jeff Winton Associates, a full-service communications agency for the pharmaceutical, biotechnology and other life sciences industries, announced expansion into additional global markets through a new partnership with UK-based marketing communications firm Onyx Health.
Bayer secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.